This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Study Type
OBSERVATIONAL
Enrollment
77
CHU Angers
Angers, France
ACTIVE_NOT_RECRUITINGCHU de Besançon
Besançon, France
RECRUITINGHôpital Avicenne
Bobigny, France
Complete histological response
Histological response rate on histological analysis of the resected specimen
Time frame: Day 1
Objectival response rate
Objectival response rate on imaging
Time frame: Day 1
Event-free survival
An event is defined by progression of the disease or toxicity making surgery impossible, the impossibility of starting adjuvant treatment within 84 days following surgery, recurrence of melanoma after surgery or death.
Time frame: Month 12
Disease Free Survival after surgery
Time frame: Month 12
Overall survival
Time frame: Month 18
Metastases-free survival
Time frame: Month 18
Frequency of toxicities
According to Common Terminology Criteria for Adverse Events (CTCAE) v5, grades III and IV
Time frame: Month 12
Severity of toxicities
According to CTCAE v5, grades III and IV
Time frame: Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CH de Boulogne-sur-Mer
Boulogne-sur-Mer, France
ACTIVE_NOT_RECRUITINGCHU Clermont-Ferrand
Clermont-Ferrand, France
ACTIVE_NOT_RECRUITINGCentre de Lutte Contre le Cancer Léon Bérard
Lyon, France
ACTIVE_NOT_RECRUITINGICO René Gauducheau
Saint-Herblain, France
ACTIVE_NOT_RECRUITINGInstitut Universitaire de Cancérologie de Toulouse
Toulouse, France
ACTIVE_NOT_RECRUITINGCH de Valence
Valence, France
ACTIVE_NOT_RECRUITING